R. Ghalib

A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Chronic Hepatitis C Virus Infection

David Gardiner, Jay Lalezari, Eric Lawitz et al. · PLoS ONE · 2013 · 227 citations · Full text

Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension

Guadalupe García–Tsao, Jaime Bosch, Zeid Kayali et al. · Journal of Hepatology · 2019 · 152 citations · Full text

Severe Portal Hypertension, Hepatology, Liver Physiology +8

1356 QUADRUPLE THERAPY WITH BMS-790052, BMS-650032 AND PEG-IFN/RBV FOR 24 WEEKS RESULTS IN 100% SVR12 IN HCV GENOTYPE 1 NULL RESPONDERS

Anna S. Lok, David Gardiner, Eric Lawitz et al. · Journal of Hepatology · 2011 · 65 citations · Full text

Viral Hepatitis, Immunology, Antiviral Therapy +5

104 BOCEPREVIR (B) COMBINATION THERAPY IN NULL RESPONDERS (NR): RESPONSE DEPENDENT ON INTERFERON RESPONSIVENESS

E. Schiff, F. Poordad, Ira M. Jacobson et al. · Journal of Hepatology · 2008 · 49 citations

Immunology, Antiviral Response, Antiviral Drug Development +6

991 FINAL RESULTS OF THE IDEAL (INDIVIDUALIZED DOSING EFFICACY VERSUS FLAT DOSING TO ASSESS OPTIMAL PEGYLATED INTERFERON THERAPY) PHASE IIIB STUDY

Mark Sulkowski, E. Läwitz, M. Shiffman et al. · Journal of Hepatology · 2008 · 47 citations

Clinical Trials, Therapeutic Efficacy, The Ideal +8